Latest Breaking News On - Jorge nieva - Page 1 : comparemela.com

Trial to test feasibility of at-home immunotherapy administration

Trial to test feasibility of at-home immunotherapy administration
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Jorge-nieva
Genentech-roche
Keck-medicine
Posted-march

Study explores the future of at-home cancer treatment

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

United-states
Sandy-tran
Jorge-nieva
Drug-administration
Norris-comprehensive-cancer-center
National-cancer-institute
Genentech-inc
Keck-medicine
Comprehensive-cancer-center
Newswise
Lincal-trial-immunotherapy-clinical-trials-cancer
Cancer

Study explores the future of at-home cancer treatment

A clinical trial from Keck Medicine of USC will test the feasibility of treating non-small cell lung cancer with immunotherapy provided at home.

United-states
Jorge-nieva
Sandy-tran
Genentech-inc
National-cancer-institute
Norris-comprehensive-cancer-center
Drug-administration
Keck-medicine
Comprehensive-cancer-center

Dr Nieva on the Rationale for Investigating At-Home Atezolizumab Administration in NSCLC

Jorge Nieva, MD, discusses the rationale and design of an ongoing phase 2 trial investigating a telemedicine approach to delivering subcutaneous atezolizumab for patients with non–small cell lung cancer.

Jorge-nieva
Keck-school-of-medicine
University-of-southern-california
Keck-school
Southern-california
D
Nct05340309
Subcutaneous-atezolizumab
Patients-with-non-small-cell-lung-cancer

FDA Panel Votes That Phase 3 PFS Data for Sotorasib in KRAS G12C+ Advanced NSCLC Cannot Be Reliably Interpreted

In a 10-to-2 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the data for progression-free survival per blinded independent central review from the phase 3 CodeBreaK 200 trial evaluating sotorasib vs docetaxel for the treatment of patients with pretreated, locally advanced or metastatic KRAS G12C–mutated non–small cell lung cancer cannot be reliably interpreted.

Markr-conaway
Jorge-nieva
Ravia-madan
Jeevan-puthiamadathil
Division-of-translational-research
University-of-virginia-school-medicine
National-cancer-institute
Keck-school-of-medicine
Statistics-department-of-public-health-sciences
University-of-southern-california
Oncologic-drugs-advisory-committee
Drugs-advisory-committee